- Home
- CCAP vs KURA Comparison
CCAP vs KURA Comparison
Compare CCAP & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCAP
- KURA
- Stock Information
- Founded
- CCAP 2015
- KURA 2014
- Country
- CCAP United States
- KURA United States
- Employees
- CCAP N/A
- KURA N/A
- Industry
- CCAP Finance: Consumer Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCAP Finance
- KURA Health Care
- Exchange
- CCAP Nasdaq
- KURA Nasdaq
- Market Cap
- CCAP 660.1M
- KURA 592.7M
- IPO Year
- CCAP N/A
- KURA N/A
- Fundamental
- Price
- CCAP $17.09
- KURA $6.60
- Analyst Decision
- CCAP Strong Buy
- KURA Strong Buy
- Analyst Count
- CCAP 5
- KURA 10
- Target Price
- CCAP $19.20
- KURA $25.50
- AVG Volume (30 Days)
- CCAP 148.6K
- KURA 1.1M
- Earning Date
- CCAP 05-07-2025
- KURA 05-01-2025
- Dividend Yield
- CCAP 1.17%
- KURA N/A
- EPS Growth
- CCAP N/A
- KURA N/A
- EPS
- CCAP 1.99
- KURA N/A
- Revenue
- CCAP $197,363,000.00
- KURA $53,883,000.00
- Revenue This Year
- CCAP N/A
- KURA $13.15
- Revenue Next Year
- CCAP N/A
- KURA $221.86
- P/E Ratio
- CCAP $8.62
- KURA N/A
- Revenue Growth
- CCAP 7.18
- KURA N/A
- 52 Week Low
- CCAP $16.64
- KURA $6.44
- 52 Week High
- CCAP $20.19
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- CCAP 34.15
- KURA 34.25
- Support Level
- CCAP $17.60
- KURA $6.95
- Resistance Level
- CCAP $17.97
- KURA $8.04
- Average True Range (ATR)
- CCAP 0.29
- KURA 0.43
- MACD
- CCAP 0.06
- KURA -0.04
- Stochastic Oscillator
- CCAP 31.46
- KURA 4.17
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.